April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer
Jan 29, 2025, 22:27

Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer

Kristina Jankovic, Medical Oncology Resident at University Clinical Center Nis, shared on X:

Phase 3 KEYNOTE756 trial –

1st interim analysis:

Pembro + chemo

pCR in high-risk early ER+/HER2− Breast Cancer (24.3% vs 15.6%)

Manageable safety

EFS data maturing.

Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial | Nature Medicine

Authors: Fatima Cardoso, Joyce O’Shaughnessy, Zhenzhen Liu, Heather McArthur, Peter Schmid, Javier Cortes, Nadia Harbeck, Melinda L. Telli, David W. Cescon, Peter A. Fasching, Zhimin Shao, Delphine Loirat, Yeon Hee Park, Manuel Gonzalez Fernandez, Gábor Rubovszky, Laura Spring, Seock-Ah Im, Rina Hui, Toshimi Takano, Fabrice André, Hiroyuki Yasojima, Yu Ding, Liyi Jia, Vassiliki Karantza, Konstantinos Tryfonidis, Aditya Bardia

Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer